Skip to main content
SpringerLink
Log in

Medical and Surgical Options in Thyroid Eye Disease

  • Chapter
  • First Online:
Book cover Manual of Oculoplastic Surgery

  • 1718 Accesses

Abstract

Thyroid eye disease (TED) is an immune-mediated disorder causing inflammation and expansion of orbital fat and muscle. The resulting spectrum of ocular and orbital changes may cause significant morbidity and is graded as disease severity. The disease follows a biphasic course with an active or progressive phase followed by a quiescent or stable phase. Appropriate management depends on an accurate and reproducible evaluation system documenting both disease severity and activity: one available method is the VISA classification. Options for managing TED include various medical therapies or radiotherapy—both of which are typically employed during the early progressive stage of the disease—and surgery, which is most commonly used during the quiescent stage, with the exception of surgery in the active phase when vision is threatened due to optic nerve compression or corneal breakdown. The VISA classification provides a logical model for choosing management based on its measurements.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 119.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Bahn RS. Graves’ ophthalmopathy. N Engl J Med. 2010;362(8):726–38.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Dolman PJ. Evaluating Graves orbitopathy. Best Pract Res Clin Endocrinol Metab. 2012;26(3):229–48.

    Article  PubMed  Google Scholar 

  3. Gerding MN, Terwee CB, Dekker FW, Koornneef L, Prummel MF, Wiersinga WM. Quality of life in patients with Graves’ ophthalmopathy is markedly decreased: measurement by the medical outcomes study instrument. Thyroid. 1997;7(6):885–9.

    Article  CAS  PubMed  Google Scholar 

  4. Bartley GB. The epidemiologic characteristics and clinical course of ophthalmopathy associated with autoimmune thyroid disease in Olmsted County, Minnesota. Trans Am Ophthalmol Soc. 1994;92:477–588.

    PubMed  PubMed Central  CAS  Google Scholar 

  5. Kendall-Taylor P, Perros P. Clinical presentation of thyroid associated orbitopathy. Thyroid. 1998;8:427–8.

    Article  CAS  PubMed  Google Scholar 

  6. Fatourechi V, Pajouhi M, Fransway AF. Dermopathy of Graves disease (pretibial myxedema). Review of 150 cases. Medicine (Baltimore). 1994;73(1):1–7.

    Article  CAS  Google Scholar 

  7. Smith TJ. TSH-receptor-expressing fibrocytes and thyroid-associated ophthalmopathy. Nat Rev Endocrinol. 2015;11:171–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Pritchard J, Horst N, Cruikshank W, Smith TJ. Igs from patients with Graves’ disease induce the expression of T cell chemoattractants in their fibroblasts. J Immunol. 2002;168:942–50.

    Article  CAS  PubMed  Google Scholar 

  9. Pritchard J, Han R, Horst N, Cruikshank W, Smith TJ. Immunoglobulin activation of T cell chemoattractant expression in fibroblasts from patients with Graves’ disease is mediated through the insulin-like growth factor 1 receptor pathway. J Immunol. 2003;170:6348–54.

    Article  CAS  PubMed  Google Scholar 

  10. Dolman PJ, Rootman J. Ch 18. Predictors of disease severity in thyroid-related orbitopathy. In: Rootman J, editor. Orbital disease. Present status and future challenges. Boca Raton: Taylor and Francis; 2005.

    Google Scholar 

  11. Stan MN, Bahn RS. Risk factors for development or deterioration of Graves’ ophthalmopathy. Thyroid. 2010;20:771–83.

    Article  Google Scholar 

  12. Rundle FF. Development and course of exophthalmos and ophthalmoplegia in Graves’ disease with special reference to the effect of thyroidectomy. Clin Sci. 1945;5:177–94.

    PubMed  CAS  Google Scholar 

  13. Dolman PJ. Assessment and management plan for Graves’ orbitopathy. In: Bahn RS, editor. Graves’ disease: a comprehensive guide for clinicians. New York: Springer Science + Business Media; 2015.

    Google Scholar 

  14. Selva D, Chen C, King G. Late reactivation of thyroid orbitopathy. Clin & Exp Ophthalmol. 2004;32(1):46–50.

    Article  Google Scholar 

  15. Bahn RS, Kazim M. Thyroid eye disease. In: Fay A, Dolman PJ, editors. Diseases and disorders of the orbit and ocular adnexa. London: Elsevier; 2017.

    Google Scholar 

  16. Regensburg NI, Wiersinga WM, Berendschot TT, Saeed P, Mourits MP. Densities of orbital fat and extraocular muscles in graves orbitopathy patients and controls. Ophthal Plast Reconstr Surg. 2011;27(4):236–40.

    Article  PubMed  Google Scholar 

  17. Polito E, Leccisotti A. MRI in Graves orbitopathy; recognition of enlarged muscles and prediction of steroid response. Ophthalmologica. 1995;209:182–6.

    Article  CAS  PubMed  Google Scholar 

  18. Werner SC. Classification of the eye changes of Graves’ disease. American J Ophthalmology. 1969;68:646–8.

    Article  CAS  Google Scholar 

  19. Boboridis K, Perros P. General management plan in Graves’ orbitopathy: a multidisciplinary approach. Basel: Karger; 2007. p. 88–95.

    Book  Google Scholar 

  20. Mourits MP, Prummel MF, Wiersinga WM, Koornneef L. Clinical activity score as a guide in the management of patients with Graves’ ophthalmopathy. Clin Endocrinol. 1997;47:9.

    Article  CAS  Google Scholar 

  21. Martins JRM, Furlanetto RP, Oliveira LM, Mendes A, Passerotti CC, Chiamolera MI, et al. Comparison of practical methods for urinary glycosaminoglycans and serum hyaluronan with clinical activity scores in patients with Graves’ ophthalmopathy. Clin Endocrinol. 2004;60:726–33.

    Article  CAS  Google Scholar 

  22. Dolman PJ, Rootman J. VISA classification for Graves orbitopathy. Ophthal Plast Reconstr Surg. 2006;22:319–24.

    Article  PubMed  Google Scholar 

  23. Wiersinga WM. Management of Graves’ ophthalmopathy. Nat Clin Pract Endocrinol Metab. 2007;3:396–404.

    Article  CAS  PubMed  Google Scholar 

  24. Bartalena L, Marcocci C, Bogazzi F, Panicucci M, Lepri A, Pinchera A. Use of corticosteroids to prevent progression of Graves’ ophthalmopathy after radioiodine therapy for hyperthyroidism. N Engl J Med. 1989;321:1349–52.

    Article  CAS  PubMed  Google Scholar 

  25. Yang DD, Gonzalez MO, Durairaj VD. Medical management of thyroid eye disease. Saudi J Ophthalmol. 2011;25(1):3–13.

    Article  PubMed  Google Scholar 

  26. Kahaly GJ, Pitz S, Hommel G, Dittmar M. Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves’ orbitopathy. J Clin Endocrinol Metab. 2005;90:5234–40.

    Article  CAS  PubMed  Google Scholar 

  27. Marinó M, Morabito E, Brunetto MR, Bartalena L, Pinchera A, Marocci C. Acute and severe liver damage associated with intravenous glucocorticoid pulse therapy in patients with Graves’ ophthalmopathy. Thyroid. 2004;14:403–6.

    Article  PubMed  Google Scholar 

  28. Ebner R, Devoto MH, Weil D, Bordaberry M, Mir C, Martinez H, et al. Treatment of thyroid associated ophthalmopathy with periocular injections of triamcinolone. Br J Ophthalmol. 2004;88:1380–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Stiebel-Kalish H, Robenshtok E, Hasanreisoglu M, Ezrachi D, Shimon I, Leibovici L. Treatment modalities for Graves’ ophthalmopathy: systematic review and meta-analysis. J Clin Endocrinol Metab. 2009;94(8):2708–16.

    Article  CAS  PubMed  Google Scholar 

  30. Shams PN, Ma R, Pickles T, Rootman J, Dolman PJ. Reduced risk of compressive optic neuropathy using orbital radiotherapy in patients with active thyroid eye disease. Am J Ophthalmol. 2014;157:1299–305.

    Article  PubMed  Google Scholar 

  31. Kahaly G, Schrezenmeir J, Krause U, Schweikert B, Meuer S, Muller W, et al. Cyclosporin and prednisone versus prednisone in treatment of Graves’ ophthalmopathy: a controlled, randomized and prospective study. Eur J Clin Investig. 1986;16:415–22.

    Article  CAS  Google Scholar 

  32. Baschieri L, Antonelli A, Nardi S, Alberti B, Lepri A, Canapicchi R, et al. Intravenous immunoglobulin versus corticosteroid in treatment of Graves’ ophthalmopathy. Thyroid. 1997;7:579–85.

    Article  CAS  PubMed  Google Scholar 

  33. Salvi M. Immunotherapy for Graves’ ophthalmopathy. Curr Opin Endocrinol Diabetes Obes. 2014;21:409–14.

    Article  CAS  PubMed  Google Scholar 

  34. Stan MN, Garrity JA, Carranza Leon BG, Prabin T, Bradley EA, Bahn RS. Randomized controlled trial of rituximab in patients with Graves’ orbitopathy. J Clin Endocrinol Metab. 2015;100:432–41.

    Article  CAS  PubMed  Google Scholar 

  35. Salvi M, Vannucchi G, Currò N, Campi I, Covelli D, Dazzi D, et al. Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves’ orbitopathy: a randomized controlled study. J Clin Endocrinol Metab. 2015;100:422–31.

    Article  CAS  PubMed  Google Scholar 

  36. Marcocci C, Kahaly GJ, Krassas GE, Bartalena L, Prummel M, Stahl M, European Group on Graves’ Orbitopathy, et al. Selenium and the course of mild Graves’ orbitopathy. N Engl J Med. 2011;364:1920–31.

    Article  CAS  PubMed  Google Scholar 

  37. Dolman PJ, Rath S. Orbital radiotherapy for thyroid eye disease. Curr Opin Ophthalmol. 2012;23(5):427–32.

    Article  PubMed  Google Scholar 

  38. Jeon C, Shin JH, Woo KI, Kim YD. Clinical profile and visual outcomes after treatment in patients with dysthyroid optic neuropathy. Korean J Ophthalmol. 2012;26(2):73–9.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Behbehani R, Sergott RC, Savino PJ. Orbital radiotherapy for thyroid-related orbitopathy. Curr Opin Ophthalmol. 2004;15:479–82.

    Article  PubMed  Google Scholar 

  40. Marcocci C, Bartalena L, Bogazzi F, Bruno-Bossio G, Lepri A, Pinchera A. Orbital radiotherapy combined with high dose systemic glucocorticoids for Graves’ ophthalmopathy is more effective than radiotherapy alone: results of a prospective randomized study. J Endocrinol Investig. 1991;14:853–60.

    Article  CAS  Google Scholar 

  41. Prummel MF, Terwee CB, Gerding MN, Baldeschi L, Mourits MP, Blank L, et al. A randomized controlled trial of orbital radiotherapy versus sham irradiation in patients with mild Graves’ ophthalmopathy. J Clin Endocrinol Metab. 2004;89:15–20.

    Article  CAS  PubMed  Google Scholar 

  42. Mourits MP, van Kempen-Harteveld ML, Garcia MB, Koppeschaar HP, Tick L, Terwee CB. Radiotherapy for Graves’ orbitopathy: randomised placebo-controlled study. Lancet. 2000;355:1505–9.

    Article  CAS  PubMed  Google Scholar 

  43. Gorman CA, Garrity JA, Fatourechi V, Bahn RS, Petersen IA, Stafford SL, et al. A prospective, randomized, double-blind, placebo-controlled study of orbital radiotherapy for Graves’ ophthalmopathy. Ophthalmology. 2001;108:1523–34.

    Article  CAS  PubMed  Google Scholar 

  44. Wakelkamp I, Tan H, Saeed P, Schlingemann RO, Verbraak FD, Blank LE, et al. Orbital irradiation for Graves’ ophthalmopathy: is it safe? A long-term follow-up study. Ophthalmology. 2004;111:1557–62.

    Article  PubMed  Google Scholar 

  45. Gillis CC, Chang EH, Al-Kharazi K, Pickles T. Secondary malignancy following radiotherapy for thyroid eye disease. Rep Pract Oncol Radiother. 2016;21(3):156–6.

    Google Scholar 

  46. Fayers T, Barker LE, Verity DH, Rose GE. Oscillopsia after lateral wall orbital decompression. Ophthalmology. 2013;120(9):1920–3.

    Article  PubMed  Google Scholar 

  47. Fayers T, Dolman PJ. Validity and reliability of the TED-QOL: a new 3-item questionnaire to assess quality of life in thyroid eye disease. Br J Ophthalmol. 2011;95:1670–4.

    Article  PubMed  Google Scholar 

  48. Fayers T, Fayers PM, Dolman PJ. Sensitivity and responsiveness of the patient-reported TED-QOL to rehabilitative surgery in thyroid eye disease. Orbit. 2016;35(6):328–34.

    Article  PubMed  Google Scholar 

  49. Peragallo JH, Velez FG, Demer JL, Pineles SL. Postoperative drift in patients with thyroid ophthalmopathy undergoing unilateral inferior rectus muscle recession. Strabismus. 2013;21(1):23–8.

    Article  PubMed  PubMed Central  Google Scholar 

  50. Davies MJ, Dolman PJ. Levator muscle enlargement in thyroid eye disease-related upper eyelid retraction. Ophthal Plast Reconstr Surg. 2017;33(1):35–9.

    Article  PubMed  Google Scholar 

  51. Khanna D, Chong KK, Afifiyan NF, Hwang CJ, Lee DK, Garneau HC, et al. Rituximab treatment of patients with severe, corticosteroid-resistant thyroid-associated ophthalmopathy. Ophthalmology. 2010;117(1):133–9.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Oculoplastics and Orbit, Department of Ophthalmology and Visual Sciences, University of British Columbia, Eye Care Center, Vancouver, BC, Canada

    Peter J. Dolman

Authors
  1. Peter J. Dolman
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Case Western Reserve University School of Medicine, Cleveland Clinic Foundation, Cleveland, Ohio, USA

    Mark R. Levine

  2. Department of Ophthalmology, Cullen Eye Institute, Baylor College of Medicine, Houston, Texas, USA

    Richard C. Allen

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Dolman, P.J. (2018). Medical and Surgical Options in Thyroid Eye Disease. In: Levine, M., Allen, R. (eds) Manual of Oculoplastic Surgery. Springer, Cham. https://doi.org/10.1007/978-3-319-74512-1_54

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-74512-1_54

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-74511-4

  • Online ISBN: 978-3-319-74512-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation